Date:
October 4, 2021
Issue #:
1634
Summary:
The FDA has approved a long-acting fixed-dose
combination of the stimulant dexmethylphenidate
and the prodrug serdexmethylphenidate (Azstarys –
Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years
old. Azstarys is the first product containing serdexmethylphenidate
to become available in the US.
combination of the stimulant dexmethylphenidate
and the prodrug serdexmethylphenidate (Azstarys –
Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years
old. Azstarys is the first product containing serdexmethylphenidate
to become available in the US.
